Praveen Anand

Praveen is Professor of Clinical Neurology at Imperial College London, based at Hammersmith Hospital. His medical education was at the Universities of Oxford and Cambridge, UK, and post-graduate training was at the Hammersmith Hospital and the National Hospital for Neurology and Neurosurgery, Queen Square, London. His research focuses on pathophysiological and molecular mechanisms in the human sensory neuropathies and chronic pain syndromes.

Collaborations with pharmaceutical companies are directed to translational projects and new techniques which bridge the gap between pre-clinical developments and successful clinical applications. The techniques of assessment have included contact heat evoked potentials (CHEPS) and molecular markers in skin biopsies.

Clinical trials have been conducted using novel compounds for pain and nerve regeneration with several companies, including GlaxoSmithKline, Genentech, Roche, and Amgen.

He has over 150 peer reviewed publications in journals including Nature, Nature Medicine, Nature Genetics, The Lancet, and Science.Praveen is conducting fundamental pharmacology studies on the AT2 receptor in human tissue as well as providing clinical leadership into the Phase 2 program for EMA401.

Praveen Anand is the Scientific Advisor at Spinifex Pharmaceuticals, based in Europe. With a background in Biotechnology, Praveen Anand has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.